) The Transgenic/Knockout Shared Core Resource is an expansion from the existing transgenic mouse core laboratory to include targeted gene disruption using homologous recombination in embryonic stem (ES) cells and the generation of """"""""knockout"""""""" mice. The facility will also support the in vitro differentiation of ES cells. This core, which began operation in 1990, now consists of has an ES cell/targeted gene disruption facility and a microinjection laboratory. The core provides all the necessary services to support the generation, maintenance, breeding and preservation of transgenic and germ line positive knockout mice. Over the past four and one-half years, the transgenic component of this resource has served 25 different Cancer Center Investigators and generated 241 transgenic founders representing 44 constructs. The new ES cell/gene disruption facility has recently generated four germ line positive knockout mouse lines. In addition, the ES cell laboratory provides technical expertise in growth of ES cells and targeted gene disruption using homologous recombination and instruction of investigators in methods of in vitro ES cell differentiation. The core also provides embryo cryopreservation, strain rederivation, training of Cancer Center investigators, their graduate and postdoctoral students in transgenic technology, models and genetics. This component also provides colony management and maintenance, automated pedigree management, and breeding of all transgenic founders, knockout and experimental breeding colonies. The Transgenic/Knockout core presents a comprehensive service available to Cancer Center investigators for manipulation of the mouse genome. The primary goal is to maintain a state-of-the-art Transgenic/Knockout facility in the Cancer Center that is affordable and accessible to investigators for their studies in cancer biology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA046934-15S1
Application #
6664445
Study Section
Subcommittee G - Education (NCI)
Project Start
2002-05-06
Project End
2003-01-31
Budget Start
Budget End
Support Year
15
Fiscal Year
2002
Total Cost
$250,404
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Roof, Allyson K; Jirawatnotai, Siwanon; Trudeau, Tammy et al. (2018) The Balance of PI3K and ERK Signaling Is Dysregulated in Prolactinoma and Modulated by Dopamine. Endocrinology 159:2421-2434
McCubbrey, Alexandra L; Barthel, Lea; Mohning, Michael P et al. (2018) Deletion of c-FLIP from CD11bhi Macrophages Prevents Development of Bleomycin-induced Lung Fibrosis. Am J Respir Cell Mol Biol 58:66-78
Fitzpatrick, Rikki L; Quimby, Jessica M; Benson, Kellyi K et al. (2018) In vivo and in vitro assessment of mirtazapine pharmacokinetics in cats with liver disease. J Vet Intern Med 32:1951-1957
Lee, Kyubum; Kim, Byounggun; Choi, Yonghwa et al. (2018) Deep learning of mutation-gene-drug relations from the literature. BMC Bioinformatics 19:21
Johnson, Monica; Alsaleh, Nasser; Mendoza, Ryan P et al. (2018) Genomic and transcriptomic comparison of allergen and silver nanoparticle-induced mast cell degranulation reveals novel non-immunoglobulin E mediated mechanisms. PLoS One 13:e0193499
Kimball, Abigail K; Oko, Lauren M; Bullock, Bonnie L et al. (2018) A Beginner's Guide to Analyzing and Visualizing Mass Cytometry Data. J Immunol 200:3-22
Parrish, Janet K; McCann, Tyler S; Sechler, Marybeth et al. (2018) The Jumonji-domain histone demethylase inhibitor JIB-04 deregulates oncogenic programs and increases DNA damage in Ewing Sarcoma, resulting in impaired cell proliferation and survival, and reduced tumor growth. Oncotarget 9:33110-33123
Herbst, Roy S; Redman, Mary W; Kim, Edward S et al. (2018) Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. Lancet Oncol 19:101-114
Giles, Erin D; Jindal, Sonali; Wellberg, Elizabeth A et al. (2018) Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer. Breast Cancer Res 20:50
Nemkov, Travis; Sun, Kaiqi; Reisz, Julie A et al. (2018) Hypoxia modulates the purine salvage pathway and decreases red blood cell and supernatant levels of hypoxanthine during refrigerated storage. Haematologica 103:361-372

Showing the most recent 10 out of 1634 publications